United Therapeutics (UTHR) Stock Price
United Therapeutics Price
Over the last 19 years United Therapeutics grew revenue by 17.1% annually, reaching 3.18 B USD. Earnings per share have grown at 15.7% per year over the last 19 years. For United Therapeutics, the net margin of 41.9% is up versus 28.2% a few years ago. The consensus 12-month price target for United Therapeutics is 625.00 USD, about 26.4% above where the stock trades today. Of 22 analysts, 18 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.
United Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of United Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how United Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing United Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | United Therapeutics Price |
|---|---|
| 9/18/2026 | 494.63 USD |
| 9/17/2026 | 497.27 USD |
| 9/16/2026 | 500.15 USD |
| 9/15/2026 | 501.20 USD |
| 9/14/2026 | 503.88 USD |
| 9/11/2026 | 499.20 USD |
| 9/10/2026 | 503.86 USD |
| 9/9/2026 | 506.82 USD |
| 9/8/2026 | 498.17 USD |
| 9/4/2026 | 491.63 USD |
| 9/3/2026 | 490.24 USD |
| 9/2/2026 | 492.02 USD |
| 9/1/2026 | 512.70 USD |
| 8/31/2026 | 511.00 USD |
| 8/28/2026 | 518.08 USD |
| 8/27/2026 | 520.09 USD |
| 8/26/2026 | 516.68 USD |
| 8/25/2026 | 518.53 USD |
| 8/24/2026 | 512.28 USD |
| 8/21/2026 | 513.12 USD |
| 8/20/2026 | 521.00 USD |
| 8/19/2026 | 523.68 USD |
| 8/18/2026 | 514.89 USD |
| 8/14/2026 | 499.73 USD |
| 8/13/2026 | 501.27 USD |
| 8/12/2026 | 511.72 USD |
| 8/11/2026 | 515.50 USD |
| 8/10/2026 | 527.90 USD |
| 8/7/2026 | 538.84 USD |
| 8/6/2026 | 532.94 USD |
United Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
United Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.47 | 1.60 | 1.73 | 1.63 | 1.45 | 1.48 | 1.69 | 1.94 | 2.33 | 2.88 | 3.18 | 3.15 | 3.44 | 3.94 | 4.73 | 5.79 |
| 13.74 | 9.08 | 7.95 | -5.68 | -11.00 | 2.42 | 13.62 | 14.90 | 20.20 | 23.64 | 10.60 | -1.13 | 9.38 | 14.39 | 20.15 | 22.50 |
| 95.29 | 95.49 | 93.86 | 87.83 | 91.92 | 92.72 | 92.76 | 92.41 | 88.96 | 89.22 | 87.93 | 87.93 | 87.93 | 87.93 | 87.93 | 87.93 |
| 1.40 | 1.53 | 1.62 | 1.43 | 1.33 | 1.38 | 1.56 | 1.79 | 2.07 | 2.57 | 2.80 | 2.77 | 3.03 | 3.46 | 4.16 | 5.09 |
| 0.70 | 1.06 | 0.81 | 0.81 | -0.19 | 0.59 | 0.56 | 0.98 | 1.18 | 1.38 | 1.52 | 1.65 | 1.81 | 2.28 | 2.63 | 3.27 |
| 47.71 | 66.40 | 47.19 | 49.48 | -12.91 | 39.99 | 33.06 | 50.57 | 50.88 | 47.86 | 47.67 | 52.35 | 52.48 | 57.80 | 55.68 | 56.50 |
| 0.65 | 0.71 | 0.42 | 0.59 | -0.10 | 0.51 | 0.48 | 0.73 | 0.98 | 1.20 | 1.33 | 1.27 | 1.40 | 1.68 | 2.04 | 2.55 |
| 91.47 | 9.52 | -41.51 | 41.25 | -117.66 | -594.23 | -7.59 | 53.05 | 35.35 | 21.44 | 11.63 | -5.17 | 10.75 | 19.99 | 21.59 | 24.71 |
| 49.75 | 45.40 | 43.80 | 44.00 | 44.00 | 45.10 | 47.80 | 49.40 | 49.80 | 48.70 | 47.90 | 47.90 | 47.90 | 47.90 | 47.90 | 47.90 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales United Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue United Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare United Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares United Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against United Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
United Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
United Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
United Therapeutics business model & stock analysis
United Therapeutics SWOT Analysis
Strengths
1. Established Presence: United Therapeutics Corp has gained a strong footing in the pharmaceutical industry through its years of operation.
2. Diverse Product Portfolio: The company offers a wide range of medications and therapies, catering to various medical conditions and patient needs.
3. Robust Research and Development: United Therapeutics Corp maintains a strong focus on innovation and continually invests in R&D to develop new treatments.
4. Strong Financial Performance: The company has consistently delivered solid financial results, which provides stability and resources for future growth.
Weaknesses
1. Dependence on a Limited Product Range: Despite having a diverse portfolio, United Therapeutics Corp relies heavily on a few key products for the majority of its revenue.
2. High Production Costs: The manufacturing process of certain medications can be expensive, resulting in lower profit margins for the company.
3. Vulnerability to Regulatory Changes: Strict regulations and evolving compliance requirements in the pharmaceutical industry may pose challenges for United Therapeutics Corp.
4. Limited Global Market Reach: The company's operations are primarily focused in specific regions, potentially hindering growth opportunities in untapped markets.
Opportunities
1. Growing Demand for Innovative Therapies: With the increasing prevalence of various medical conditions, there is a significant market demand for new and improved treatment options.
2. Expansion into International Markets: United Therapeutics Corp can explore new markets globally to extend its reach and tap into potential revenue streams.
3. Strategic Partnerships and Collaborations: Forming alliances with other pharmaceutical companies or research institutions can enhance research capabilities and facilitate product development.
4. Technological Advancements: Incorporating cutting-edge technologies into its product offerings can help United Therapeutics Corp stay competitive and meet evolving patient needs.
Threats
1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share, which may impact United Therapeutics Corp's growth prospects.
2. Patent Expirations: The expiration of patents for certain medications may lead to increased competition from generic drug manufacturers, potentially reducing the company's market share.
3. Regulatory and Legal Challenges: United Therapeutics Corp must navigate complex regulations, potential legal disputes, and ongoing compliance requirements for its products.
4. Economic Uncertainty: Economic fluctuations and changes in healthcare policies can affect customer purchasing power and reimbursement rates, impacting the company's revenue.
United Therapeutics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
United Therapeutics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
United Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
United Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down United Therapeutics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in United Therapeutics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare United Therapeutics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
United Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
United Therapeutics stock splits
Since 2009, a total of 2 shares have been converted from one United Therapeutics share.
Current United Therapeutics forecasts and price targets in September 2026
Analyst Price Targets 2026United Therapeutics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/6/2026 | Maintained | Outperform | 48 | |
| 7/23/2026 | Maintained | Overweight | 53 | |
| 7/10/2026 | Maintained | Neutral | 60 | |
| 7/7/2026 | Maintained | Outperform | 48 | |
| 5/7/2026 | Upgrade | Equal WeightOverweight | 58 | |
| 5/7/2026 | Maintained | Outperform | 48 | |
| 4/10/2026 | Maintained | Equal Weight | 46 | |
| 3/31/2026 | Maintained | Equal Weight | 58 | |
| 3/31/2026 | Maintained | Buy | – | |
| 3/31/2026 | Maintained | Neutral | 60 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
United Therapeutics Earnings Calls
United Therapeutics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/4/2026 | 6.44USD | - | 789.51 MUSD | - | 2026 Q3 |
| 8/5/2026 | 6.86USD | 7.27USD | 804.65 MUSD | - | 2026 Q2 |
| 5/6/2026 | 7.00USD | 5.82USD | 797.40 MUSD | - | 2026 Q1 |
| 2/25/2026 | 7.13USD | 7.70USD | 813.08 MUSD | - | 2025 Q4 |
| 10/29/2025 | 6.89USD | 7.16USD | 814.80 MUSD | - | 2025 Q3 |
| 7/30/2025 | 7.29USD | 6.41USD | 801.87 MUSD | - | 2025 Q2 |
| 4/30/2025 | 6.29USD | 6.63USD | 778.66 MUSD | - | 2025 Q1 |
| 2/26/2025 | 6.40USD | 6.19USD | 734.73 MUSD | - | 2024 Q4 |
| 10/30/2024 | 6.43USD | 6.39USD | 722.62 MUSD | - | 2024 Q3 |
| 7/31/2024 | 6.40USD | 5.85USD | 691.87 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the United Therapeutics stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
United Therapeutics shareholder structure
| % | Name |
|---|---|
11.13330% | |
5.42268% | |
4.66855% | |
4.13143% | |
4.03616% | |
3.80199% |
United Therapeutics Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
37.80% | SEC ↗ | |
10.17% | SEC ↗ | |
9.40% | SEC ↗ | |
9.24% | SEC ↗ | |
8.50% | SEC ↗ | |
7.14% | SEC ↗ | |
6.89% | SEC ↗ | |
6.80% | SEC ↗ | |
6.70% | SEC ↗ | |
6.70% | SEC ↗ |
United Therapeutics Executives and Management Board
15 members · avg. age 68 · 33 % women
Dr. Martine Rothblatt (70)
Chairman of the Board, Chief Executive Officer · since 1996
23.01 M USD
Management
Mr. Michael Benkowitz (53)
President, Chief Operating Officer
Mr. James Edgemond (58)
Chief Financial Officer, Treasurer
Mr. Paul Mahon (61)
Executive Vice President, General Counsel, Corporate Secretary
Board of Directors
Ms. Jan Malcolm (68)
Director
Mr. Christopher Patusky (61)
Lead Independent Vice Chairman of the Board
Mr. Christopher Causey (62)
Independent Director
Mr. Richard Giltner (61)
Independent Director
Dr. Judy Olian (73)
Independent Director
Prof. Nilda Mesa (65)
Independent Director
United Therapeutics Supply Chain
United Therapeutics Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.16 | 0.77 | 0.93 | ||
| 2 | 0.55 | 0.87 | 0.93 | ||
| 3 | 0.62 | 0.74 | 0.90 | ||
| 4 | 0.16 | 0.78 | 0.89 | ||
| 5 | 0.01 | 0.27 | 0.77 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Smiths Group plc | — | — | — | |
| 2 | Toray Industries, Inc. | — | — | — | |
| 3 | 0.09 | -0.40 | -0.52 | ||
| 4 | -0.10 | 0.25 | -0.31 |
Frequently asked questions about United Therapeutics
The business model of United Therapeutics Corp revolves around the development and commercialization of innovative therapies for patients with life-threatening conditions. The company focuses on the research, regulatory approval, manufacturing, and marketing of pharmaceutical products, primarily in the field of pulmonary arterial hypertension (PAH). United Therapeutics Corp collaboratively works with physicians, patients, and regulatory agencies to bring life-saving treatments to the market. By employing a patient-centric approach and leveraging advanced scientific technologies, United Therapeutics Corp aims to provide effective therapeutic options for individuals suffering from PAH and other critical diseases.
United Therapeutics Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of United Therapeutics Corp in the market include companies like Gilead Sciences Inc., Actelion Pharmaceuticals Ltd., and Bayer AG.
United Therapeutics Corp is a leading biotechnology company specializing in the development of innovative therapies for patients with serious medical conditions. Founded in 1996 by Martine Rothblatt, the company has a rich history of pioneering advancements in the field of pulmonary arterial hypertension (PAH) and other rare diseases. United Therapeutics focuses on the research, development, and commercialization of drugs and devices that address the unmet needs of patients worldwide. With a mission to provide hope and improved quality of life, United Therapeutics Corp has successfully introduced several groundbreaking therapies, establishing itself as a trusted global healthcare provider.
Founded in 1996, United Therapeutics Corp has achieved several significant milestones. The company developed Remodulin®, a treatment for pulmonary arterial hypertension (PAH) that received FDA approval in 2002. In the following years, the company successfully launched Tyvaso® and Adcirca®, adding to their portfolio of PAH therapies. Moreover, United Therapeutics Corp pioneered the development of Ex-vivo Lung Perfusion (EVLP) technology, which improves the quality of donor lungs for transplantation. The company's efforts in advancing PAH treatments and lung transplantation techniques have greatly impacted the medical field, making United Therapeutics Corp a global leader in the pharmaceutical industry.
United Therapeutics Corp is primarily present in the United States.
United Therapeutics Corp is committed to delivering innovative solutions in the field of biotechnology. With a strong emphasis on patient care and well-being, the company strives to improve the lives of individuals suffering from severe medical conditions. United Therapeutics Corp's corporate philosophy revolves around cultivating a culture of excellence, fostering a collaborative approach, and maintaining a steadfast dedication to scientific research and development. By consistently pushing boundaries and working towards groundbreaking advancements, United Therapeutics Corp aims to provide hope and transformative therapies for patients worldwide.
Analysts currently set an average price target of 635.00 USD for the United Therapeutics stock (median: 625.00 USD), implying +28.0 % versus the latest price. The consensus is based on 22 analyst ratings.
22 analysts currently rate the United Therapeutics stock: 18 recommend buying, 4 holding and 0 selling. For 2026, analysts expect United Therapeutics to generate revenue of 3.15 B USD and earnings per share of 26.42 USD.
Converted at the current exchange rate, the United Therapeutics share trades at 430.97 EUR (494.63 USD).
The United Therapeutics share (UTHR) is listed on 5 stock exchanges, including: NASDAQ (UTHR), SIX (Zürich) (UTH.SW), Frankfurt (UTH.F), München (UTH.MU), Düsseldorf (UTH.DU).
United Therapeutics Corp is a leading biotechnology company focused on the development and commercialization of innovative therapies for rare and serious diseases. The company has been pursuing a dual-track strategy since its founding in 1996, which includes both the development of novel drugs and the marketing of already approved products. United Therapeutics' core business focuses on developing drugs for the treatment of lung diseases. The company has specialized particularly in pulmonary hypertension, a rare condition in which high blood pressure in the pulmonary arteries leads to narrowing of the blood vessels and can occur especially in young women. Treatment options for pulmonary hypertension have been limited for a long time, but United Therapeutics has made a breakthrough with its various products. One of United Therapeutics' best-known products is Remodulin, an intravenous medication for the treatment of pulmonary arterial hypertension (PAH) that was already approved in 2002. In addition to Remodulin, the company has also introduced Tyvaso, which is administered as a handheld inhaler and offers patients more flexibility in dosage and application. Another product for the treatment of pulmonary hypertension is Orenitram, an oral medication developed for patients who have difficulty using intravenous medications or inhalers. In addition to developing new drugs, United Therapeutics is also working on further developing and improving existing products. An example of this is the implant for partial lung replacement developed by its subsidiary Lung Biotechnology PBC. The implant contains living cells from a donor lung and is implanted into the body to support the function of the heart-lung system and bridge the time until transplantation. Another focus of United Therapeutics is advancing xenotransplantation, in which organs from animals are to be transplanted into humans. The company has already made significant progress in this field and is closely collaborating with other companies and organizations to further improve this technology. Overall, United Therapeutics' business model is focused on long-term growth and the development of innovative therapies. The company invests heavily in research and development and works closely with customers, partners, and other companies to develop groundbreaking solutions for serious and rare diseases. Through its close collaboration with physicians, research institutes, and patient organizations, the company strives to provide patients worldwide with access to life-saving therapies while also providing its shareholders with solid returns.
The expected revenue of United Therapeutics is 3.15 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of United Therapeutics is 1.27 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of United Therapeutics is currently 18.72. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the United Therapeutics stock.
The price-to-sales ratio (P/S) of United Therapeutics is currently 7.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the United Therapeutics stock.
The Eulerpool Quality Score for United Therapeutics is 6/10.
The ISIN of United Therapeutics is US91307C1027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of United Therapeutics is 923818. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of United Therapeutics is UTHR. The ticker symbol is used to trade United Therapeutics shares on the stock exchange.
United Therapeutics paid dividends every year for the past 0 years.
United Therapeutics is assigned to the 'Health' sector.
The dividends of United Therapeutics are distributed in USD.
United Therapeutics stock
United Therapeutics Peer Group
United Therapeutics Ticker
United Therapeutics FIGI
All fundamentals and in-depth analysis of United Therapeutics
Our stock analysis for United Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of United Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.